FDA to plug Critical Path gap

FDA issued draft guidance outlining a process for gaining regulatory acceptance of drug development tools such as biomarkers and patient reported outcome instruments. The new pathway would attempt to address a gap in FDA's Critical Path initiative, the lack of a process for gaining regulatory acceptance of new drug development tools outside of a product application. ...